Back to News
Market Impact: 0.25
Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal
Source: zacks.com
Healthcare & BiotechM&A & RestructuringTechnology & InnovationCompany Fundamentals
Novartis (NVS) gained global rights to Abogen’s ABO2203, expanding its RNA therapeutics efforts. The asset could offer a new approach to B-cell-mediated autoimmune diseases; the article provides no deal terms or clinical data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
NVS0.45
More News
- Security researcher claims to they found KVM guest-host escape flaw
- CH Robinson to Buy RXO for $5.8B in Bet on AI Model
- Nike’s China troubles: What are the implications for other sportswear brands?
- SpaceX stock climbs to highest since June, returning Musk to trillionaire status
- Schneider Electric drops $22.6B on PTC as datacenter boom rains money on infra companies
- Wells Fargo gets a bold upgrade ahead of earnings. Why the stock can play catch-up